September 1, 2023Fernando Gómez, Ian Philip Barrera, Rodolfo Maytorena-Gutiérrez et al.1 citation
Please confirm that an ethics committee approval has been applied for or granted: Not relevant (see information at the bottom of this page) Background and Aims Chronic pain presents a significant healthcare burden and can become quite debilitating. The current standards of care for chronic pain include lifestyle management, procedures, and analgesics for acute exacerbations. However, using...
Psychedelics, also known as classical hallucinogens, have been investigated for decades due to their potential therapeutic effects in the treatment of neuropsychiatric and substance use disorders. The results from clinical trials have shown promise for the use of psychedelics to alleviate symptoms of depression and anxiety, as well as to promote substantial decreases in the use of nicotine and...
Substance abuse is on the rise, and while many people may use illicit drugs mainly due to their rewarding effects, their societal impact can range from severe, as is the case for opioids, to promising, as is the case for psychedelics. Common with all these drugs' mechanisms of action are G protein-coupled receptors (GPCRs), which lie at the center of how these drugs mediate inebriation,...
Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating psychiatric disorders, including depression, addiction, post-traumatic stress disorder, and potentially others. 'Classic' serotonergic psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), which have a key locus of action at the 5-HT2A receptor, form the main focus of this...
Psilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in psychedelic-assisted therapy of several psychiatric disorders. A less explored topic concerns the use of repeated low doses of psychedelics, at a dose that is well below the psychedelic dose used in psychedelic-assisted therapy and often referred to as microdosing. Psilocybin microdose users frequently report...
Background Psilocybin has been studied for its potential therapeutic benefits, particularly for the treatment of psychiatric disorders such as anxiety, depression, and obsessive-compulsive disorder. While more research is needed as psilocybin-assisted therapy becomes more prevalent, future pharmacists will probably be involved at some level. At present, pharmacists receive minimal training on...
Background: Psychological distress is prevalent among university students. However, the availability of evidence-based mental health treatment remains limited in many low- and middle-income countries, including Indonesia. Internet-delivered, mindfulness-based interventions that reduce distress have potential for treating university student distress at scale. Unfortunately, evidence-based,...
This month's announcement of up to $285 million in private placement financing for a leading developer of psychedelic drug therapies signals an important validation of this drug sector's role in mental health treatment, the biotechnology company's CEO told MHW last week.
Objective: Engaging in practices of intimacy meant to develop and sustain intimacy can be beneficial for couples. Psychoactive substances such as 3,4-Methylenedioxymethamphetamine (MDMA) have shown to facilitate bonding within couples and it is hypothesised that classic psychedelics, due to their property to increase prosocial behaviours, can similarly promote interactional intimacy. This study...